Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Note 11 - Stock and Employee Benefit Plans (Tables)

Note 11 - Stock and Employee Benefit Plans (Tables)

12 Months Ended

Dec. 31, 2022

Notes Tables

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

		*Years Ended December 31,*
		*2022*				*2021*
Risk free interest rate			1.43% - 3.39%				0.46% - 1.20%
Expected term (in years)			5.5 - 5.73				5.31 - 5.73
Dividend yield			—				—
Expected volatility			79.9% - 81.1%				75.0% - 81.7%

		*Years Ended December 31,*
		*2022*				*2021*
Risk free interest rate			1.62% - 4.60%				0.04% - 0.10%
Expected term (in years)			0.5				0.5
Dividend yield			—				—
Expected volatility			53.46% - 70.17%				60.46% - 131.21%

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

										*Weighted-*
						*Weighted-*				*Average*				*Aggregate*
						*Average*				*Remaining*				*Intrinsic*
		*Number of*				*Exercise*				*Contractual*				*Value*
		*Options*				*Price*				*Life (in years)*				*(in thousands)*
Outstanding, December 31, 2021			11,475,713			$	3.35							$	11,310
Granted			3,075,282				2.88								—
Exercised			46,233				2.07								66
Canceled			1,031,396				3.80								17
Outstanding, December 31, 2022			13,473,366			$	3.21				6.31			$	—
Vested or expected to vest, December 31, 2022			13,473,366			$	3.21				6.31			$	—
Exercisable, December 31, 2022			9,096,001			$	3.38				5.16			$	—

										*Weighted-*
						*Weighted-*				*Average*				*Aggregate*
						*Average*				*Remaining*				*Intrinsic*
		*Number of*				*Exercise*				*Contractual*				*Value*
		*Options*				*Price*				*Life (in years)*				*(in thousands)*
Outstanding, December 31, 2021			660,000			$	4.01							$	108
Granted			—			$	—							$	—
Canceled or Expired			360,000			$	3.48							$	—
Outstanding, December 31, 2022			300,000			$	4.65				6.66			$	—
Vested or expected to vest, December 31, 2022			300,000			$	4.65				6.66			$	—
Exercisable, December 31, 2022			243,750			$	4.65				6.66			$	—

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

		*Years Ended December 31,*
		*2022*				*2021*
Research and development		$	1,905			$	2,274
General and administrative			2,497				2,941
Total stock-based compensation		$	4,402			$	5,215